Efficacy and safety of teneligliptin.
作者信息
Singh Awadhesh Kumar
机构信息
Department of Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal, India.
出版信息
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):11-17. doi: 10.4103/2230-8210.193163.
Abstract
摘要
相似文献
1
Efficacy and safety of teneligliptin.替格列汀的疗效与安全性。
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):11-17. doi: 10.4103/2230-8210.193163.
2
Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.连续血糖监测评估西格列汀联合胰岛素治疗血液透析 2 型糖尿病患者的疗效和安全性。
Diabetes Res Clin Pract. 2016 Dec;122:78-83. doi: 10.1016/j.diabres.2016.10.016. Epub 2016 Oct 21.
3
Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.替格列汀治疗2型糖尿病患者的疗效与安全性：一项随机对照试验的系统评价与荟萃分析
Front Pharmacol. 2018 May 4;9:449. doi: 10.3389/fphar.2018.00449. eCollection 2018.
4
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QT/QTc" study (Q-SET study).替格列汀在印度2型糖尿病患者中的QT/QTc安全性和疗效评估：“全面QT/QTc”研究（Q-SET研究）。
Diabetes Metab Syndr Obes. 2019 Jun 21;12:961-967. doi: 10.2147/DMSO.S202458. eCollection 2019.
5
Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment.替格列汀在肾功能损害受试者中的药代动力学。
Clin Pharmacol Drug Dev. 2013 Jul;2(3):246-54. doi: 10.1002/cpdd.29. Epub 2013 May 14.
6
Teneligliptin for the treatment of type 2 diabetes.替奈利肽治疗2型糖尿病。
Drugs Today (Barc). 2013 Oct;49(10):615-29. doi: 10.1358/dot.2013.49.10.2035882.
7
Evaluation of the Safety and Efficacy of Teneligliptin at a Higher Dose in Indian Type 2 Diabetes Patients: A Retrospective Analysis.在印度2型糖尿病患者中高剂量替格列汀的安全性和有效性评估：一项回顾性分析。
Cureus. 2020 Jan 29;12(1):e6812. doi: 10.7759/cureus.6812.
8
Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.替奈利肽治疗早期糖尿病肾病：亚洲印度裔2型糖尿病患者在现实生活中的观察
J Clin Diagn Res. 2017 Jun;11(6):OC22-OC25. doi: 10.7860/JCDR/2017/27013.10003. Epub 2017 Jun 1.
9
Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.酮康唑对二肽基肽酶-4抑制剂替格列汀药代动力学的影响：德国健康白人受试者的一项开放标签研究。
Clin Ther. 2014 May;36(5):760-9. doi: 10.1016/j.clinthera.2014.03.002. Epub 2014 Apr 13.
10
Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.健康成年人稳态条件下替格列汀与二甲双胍潜在药代动力学相互作用的研究。
Clin Ther. 2015 Sep;37(9):2007-18. doi: 10.1016/j.clinthera.2015.06.012. Epub 2015 Jul 23.
引用本文的文献
1
Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach.用干细胞和抗糖尿病药物治疗 2 型糖尿病：一种二元的、着眼于未来的方法。
Hum Cell. 2024 Jan;37(1):54-84. doi: 10.1007/s13577-023-01007-0. Epub 2023 Dec 1.
2
Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.在二甲双胍控制不佳的中国 2 型糖尿病患者中，添加替格列汀治疗的疗效和安全性：一项 3 期、随机、双盲、安慰剂对照研究。
Endocrinol Diabetes Metab. 2021 Jan 20;4(2):e00222. doi: 10.1002/edm2.222. eCollection 2021 Apr.
3
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea.在韩国开展的一项真实世界研究：替格列汀对比磺脲类药物对 2 型糖尿病患者主要不良心血管结局的影响
Endocrinol Metab (Seoul). 2021 Feb;36(1):70-80. doi: 10.3803/EnM.2020.777. Epub 2021 Feb 24.
4
Teneligliptin-induced hair loss: A case report.替格列汀所致脱发：一例报告
J Family Med Prim Care. 2020 May 31;9(5):2552-2554. doi: 10.4103/jfmpc.jfmpc_65_20. eCollection 2020 May.
5
QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QT/QTc" study (Q-SET study).替格列汀在印度2型糖尿病患者中的QT/QTc安全性和疗效评估：“全面QT/QTc”研究（Q-SET研究）。
Diabetes Metab Syndr Obes. 2019 Jun 21;12:961-967. doi: 10.2147/DMSO.S202458. eCollection 2019.
6
Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.替奈利汀在2型糖尿病合并肾功能不全患者中的安全性和有效性：上市后监测中期报告
Diabetes Ther. 2018 Jun;9(3):1083-1097. doi: 10.1007/s13300-018-0416-2. Epub 2018 Apr 10.
7
Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.替奈利肽治疗早期糖尿病肾病：亚洲印度裔2型糖尿病患者在现实生活中的观察
J Clin Diagn Res. 2017 Jun;11(6):OC22-OC25. doi: 10.7860/JCDR/2017/27013.10003. Epub 2017 Jun 1.
本文引用的文献
1
Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database.二肽基肽酶-IV抑制剂诱发大疱性类天疱疮：一例报告及欧洲药物警戒数据库中报告病例的分析
J Clin Pharm Ther. 2016 Jun;41(3):368-370. doi: 10.1111/jcpt.12397.
2
Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.在肝功能损害受试者中的替格列汀药代动力学和安全性。
Clin Pharmacol Drug Dev. 2014 Jul;3(4):290-6. doi: 10.1002/cpdd.89. Epub 2014 Feb 17.
3
Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.新型二肽基肽酶-4抑制剂替奈利汀在韩国2型糖尿病患者中的疗效与安全性：一项为期24周的多中心、随机、双盲、安慰剂对照III期试验
Diabetes Obes Metab. 2016 May;18(5):528-32. doi: 10.1111/dom.12631. Epub 2016 Mar 18.
4
Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.二肽基肽酶-4抑制剂与磺脲类药物的比较综述
Diabetes Obes Metab. 2016 Apr;18(4):333-47. doi: 10.1111/dom.12610. Epub 2016 Jan 8.
5
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.替奈利汀可改善糖尿病患者的左心室舒张功能和内皮功能。
Heart Vessels. 2016 Aug;31(8):1303-10. doi: 10.1007/s00380-015-0724-7. Epub 2015 Aug 13.
6
Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.健康成年人稳态条件下替格列汀与二甲双胍潜在药代动力学相互作用的研究。
Clin Ther. 2015 Sep;37(9):2007-18. doi: 10.1016/j.clinthera.2015.06.012. Epub 2015 Jul 23.
7
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.西格列汀对 2 型糖尿病患者心血管结局的影响。
N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8.
8
Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.替格列汀在日本2型糖尿病患者中的安全性和有效性：两项III期临床研究的汇总分析
Expert Opin Pharmacother. 2015 May;16(7):971-81. doi: 10.1517/14656566.2015.1032249. Epub 2015 Apr 10.
9
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.在 EXAMINE 研究中，比较阿格列汀与安慰剂治疗 2 型糖尿病患者的心力衰竭和死亡率结局：一项多中心、随机、双盲试验。
Lancet. 2015 May 23;385(9982):2067-76. doi: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10.
10
Teneligliptin : expectations for its pleiotropic action.替格列汀：对其多效性作用的期望。
Expert Opin Pharmacother. 2015 Feb;16(3):417-26. doi: 10.1517/14656566.2015.1000301.
Zotero 插件